Truqap plus Faslodex approved in Japan for patients with advanced HR-positive breast cancer
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
The report underscores significant advancements in healthcare delivery, showcasing how GenAI facilitates improved diagnostic accuracy, operational efficiency and patient engagement
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Currently, Sharma is a part of the Philippines Country Leadership Team as Business Unit Head Respiratory & Immunology
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
Subscribe To Our Newsletter & Stay Updated